Company news

ANI Pharmaceuticals, Inc. news in 2025

ANI Pharmaceuticals, Inc.'s news releases, calls and decks from 2025, newest first.

View company

ANI Pharmaceuticals Announces Formation of “FutureVision Advisory Council” to Help Strategically Guide Ophthalmology and Retina Franchise

December 1, 2025

ANI Pharmaceuticals Announces Board Transition

November 30, 2025

ANI Pharmaceuticals to Present at the Piper Sandler 37th Annual Healthcare Conference

November 24, 2025

ANI Pharmaceuticals to Present at the Jefferies Global Healthcare Conference – London

November 10, 2025

ANI Pharmaceuticals Reports Record Third Quarter 2025 Financial Results and Raises 2025 Guidance

November 6, 2025

ANI Pharmaceuticals to Discuss Third Quarter 2025 Financial Results on November 7, 2025, at 8: 30 a.m. ET

October 23, 2025

ANI Pharmaceuticals Announces NEW DAY Clinical Trial Results to be Presented in Late-Breaking Oral Presentation at the American Academy of Ophthalmology 2025 Meeting

October 15, 2025

ANI Pharmaceuticals to Present at Upcoming Investor Conferences

August 24, 2025

ANI Pharmaceuticals Reports Record Second Quarter 2025 Financial Results and Raises 2025 Guidance

August 7, 2025

ANI Pharmaceuticals to Discuss Second Quarter 2025 Financial Results on August 8, 2025, at 8: 30 a.m. ET

July 31, 2025

ANI Pharmaceuticals Announces Results from NEW DAY Clinical Trial of ILUVIEN® for Use in Patients with Diabetic Macular Edema (DME)

July 22, 2025

ANI Pharmaceuticals to Participate at Leerink Partners Therapeutics Forum: I&I and Metabolism on July 8th

July 1, 2025

ANI Pharmaceuticals Announces Presentation of New Preclinical Data

June 11, 2025

ANI Pharmaceuticals to Present at the 2025 Jefferies Global Healthcare Conference

May 26, 2025

ANI Pharmaceuticals Announces Initiation of Phase 4 Clinical Trial of Purified Cortrophin® Gel for the Treatment of Acute Gout Flares

May 21, 2025

ANI Pharmaceuticals to Participate at the H.C. Wainwright 3rd Annual BioConnect Conference at NASDAQ

May 11, 2025

ANI Pharmaceuticals Reports Record First Quarter 2025 Financial Results and Raises 2025 Guidance

May 8, 2025

ANI Pharmaceuticals Announces Presentation of Preclinical Data on the Use of Purified Cortrophin® Gel in an Experimental Autoimmune Uveitis (EAU) Mouse Model

May 4, 2025

ANI Pharmaceuticals to Discuss First Quarter 2025 Financial Results on May 9, 2025, at 8: 00 a.m. ET

April 8, 2025

ANI Pharmaceuticals to Present at 2025 RBC Capital Markets Ophthalmology Virtual Conference

March 30, 2025

ANI Pharmaceuticals Announces the Launch of Nitazoxanide Tablets

March 18, 2025

ANI Pharmaceuticals Announces Buyout of Royalty Obligation for ILUVIEN® and YUTIQ®

March 17, 2025

ANI Pharmaceuticals Announces FDA Approval for Expansion of ILUVIEN® Label

March 13, 2025

ANI Pharmaceuticals Announces FDA Approval of New Purified Cortrophin Gel® Prefilled Syringe

March 2, 2025

ANI Pharmaceuticals Reports Record Fourth Quarter and Full-Year 2024 Financial Results and Raises 2025 Guidance

February 27, 2025

ANI Pharmaceuticals to Present at Raymond James’ Institutional Investors and Leerink Partners Global Healthcare Conferences in March

February 18, 2025

ANI Pharmaceuticals to Discuss Fourth Quarter and Full Year 2024 Financial Results on February 28, 2025, at 8: 00 a.m. ET

February 17, 2025

ANI Pharmaceuticals to Present at the Guggenheim Biotech Conference

January 27, 2025

ANI Pharmaceuticals Provides Preliminary Fourth Quarter and 2024 Financial Results and Preliminary 2025 Outlook

January 12, 2025

ANI Pharmaceuticals Announces the FDA Approval and Launch of Prucalopride Tablets with 180-Day CGT Exclusivity

January 1, 2025

Calls in 2025

Decks in 2025